DURECT Corp. (DRRX) shares soared 254.62 percent to $1.96 on Tuesday after announcing it will be acquired by Bausch Health Companies (BHC). The deal includes DURECT's lead asset, larsucosterol, a novel epigenetic modulator showing promise for treating alcoholic hepatitis, a life-threatening liver disease with no currently approved therapies.
The stock opened at $2.00 and traded between $1.93 and $2.64, with volume exploding to 41.76 million shares, far above its average of just over 100,000 on the Nasdaq. DURECT shares, which previously closed at $0.55, now sit near their 52-week high of $2.64.
The acquisition highlights growing investor confidence in larsucosterol's commercial potential and the strategic fit with Bausch's hepatology portfolio.
For comments and feedback contact: editorial@rttnews.com
Business News
December 26, 2025 08:42 ET Third quarter economic growth data from some major economies including the U.S. were the main news in this holiday shortened week. GDP growth and industrial production data from the U.S. helped to boost morale, while the consumer confidence survey results were less upbeat. In Europe, the quarterly economic growth data from the U.K. drew attention, while the minutes of the Australian central bank’s latest policy session was in focus in Asia.